YM201636PIKfyve inhibitor,potent and selective CAS# 371942-69-7 |
- YM-155 hydrochloride
Catalog No.:BCC2066
CAS No.:355406-09-6
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
| Cas No. | 371942-69-7 | SDF | Download SDF |
| PubChem ID | 9956222 | Appearance | Powder |
| Formula | C25H21N7O3 | M.Wt | 467.48 |
| Type of Compound | N/A | Storage | Desiccate at -20°C |
| Solubility | DMSO : ≥ 47 mg/mL (100.54 mM) H2O : < 0.1 mg/mL (insoluble) *"≥" means soluble, but saturation unknown. | ||
| Chemical Name | 6-amino-N-[3-(4-morpholin-4-ylpyrido[2,3]furo[2,4-b]pyrimidin-2-yl)phenyl]pyridine-3-carboxamide | ||
| SMILES | C1COCCN1C2=NC(=NC3=C2OC4=C3C=CC=N4)C5=CC(=CC=C5)NC(=O)C6=CN=C(C=C6)N | ||
| Standard InChIKey | YBPIBGNBHHGLEB-UHFFFAOYSA-N | ||
| Standard InChI | InChI=1S/C25H21N7O3/c26-19-7-6-16(14-28-19)24(33)29-17-4-1-3-15(13-17)22-30-20-18-5-2-8-27-25(18)35-21(20)23(31-22)32-9-11-34-12-10-32/h1-8,13-14H,9-12H2,(H2,26,28)(H,29,33) | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | YM201636 is a selective inhibitor of PIKfyve with an IC50 value of 33 nM. | |||||
| Targets | PIKfyve | p110α | ||||
| IC50 | 33 nM | 3.3 μM | ||||
YM201636 Dilution Calculator
YM201636 Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 2.1391 mL | 10.6956 mL | 21.3913 mL | 42.7826 mL | 53.4782 mL |
| 5 mM | 0.4278 mL | 2.1391 mL | 4.2783 mL | 8.5565 mL | 10.6956 mL |
| 10 mM | 0.2139 mL | 1.0696 mL | 2.1391 mL | 4.2783 mL | 5.3478 mL |
| 50 mM | 0.0428 mL | 0.2139 mL | 0.4278 mL | 0.8557 mL | 1.0696 mL |
| 100 mM | 0.0214 mL | 0.107 mL | 0.2139 mL | 0.4278 mL | 0.5348 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
YM201636 is a potent, selective and cell-permeable inhibitor of mammalian class III phosphatidylinositol phosphate kinase PIKfyve with IC50 value of 33nM [1].
The pyridofuropyrimidine compound, YM201636, is a small-molecule inhibitor of PIKfyve. In the in vitro assay, it inhibits PIKfyve with IC50 value of 33nM and shows no inhibition of yeast orthologue of PIKfyve. It inhibits PtdIns3P p110α and type Iα PtdInsP kinase with IC50 values of 3μM and > 2μM, respectively. The type IIγ PtdInsP kinase is found to be insensitive to YM201636. In serum-starved NIH3T3 cells, YM201636 inhibits PtdIns (3, 5) P2 production by 80% at concentration of 800nM. Acute treatment of YM201636 to MEFs, MDCK, MCF10A, COS7 and NIH3T3 cells causes the formation of large vesicular structures. Besides that, YM201636 is also found to reduce the Akt phosphorylation and GLUT4 cell surface translocation through inhibiting the insulin-dependent class I PI 3k activation [1, 2].
References:
[1] Jefferies H B J, Cooke F T, Jat P, et al. A selective PIKfyve inhibitor blocks PtdIns (3, 5) P2 production and disrupts endomembrane transport and retroviral budding. EMBO reports, 2008, 9(2): 164-170.
[2] Ikonomov O C, Sbrissa D, Shisheva A. YM201636, an inhibitor of retroviral budding and PIKfyve-catalyzed PtdIns (3, 5) P2synthesis, halts glucose entry by insulin in adipocytes. Biochemical and biophysical research communications, 2009, 382(3): 566-570.
- PI-103 Hydrochloride
Catalog No.:BCC1860
CAS No.:371935-79-4
- PI-103
Catalog No.:BCC1162
CAS No.:371935-74-9
- Flavoxate hydrochloride
Catalog No.:BCC5208
CAS No.:3717-88-2
- 4'-Amino-3',5'-dichloroacetophenone
Catalog No.:BCC8678
CAS No.:37148-48-4
- Murrangatin
Catalog No.:BCN5426
CAS No.:37126-91-3
- IC-87114
Catalog No.:BCC1161
CAS No.:371242-69-2
- Azlocillin sodium salt
Catalog No.:BCC4763
CAS No.:37091-65-9
- Procyanidin C1
Catalog No.:BCN6317
CAS No.:37064-30-5
- Z-Glu-OBzl
Catalog No.:BCC2780
CAS No.:3705-42-8
- Cyclo(Gly-L-Pro)
Catalog No.:BCN4059
CAS No.:3705-27-9
- Cyclo(L-Phe-L-Pro)
Catalog No.:BCN4029
CAS No.:3705-26-8
- Carbetocin
Catalog No.:BCC6304
CAS No.:37025-55-1
- ZAPA sulfate
Catalog No.:BCC6563
CAS No.:371962-01-5
- SB 612111 hydrochloride
Catalog No.:BCC7714
CAS No.:371980-94-8
- L-Citruline
Catalog No.:BCN2692
CAS No.:372-75-8
- Capsidiol
Catalog No.:BCC8140
CAS No.:37208-05-2
- Citromycin
Catalog No.:BCN7459
CAS No.:37209-30-6
- PIK-75
Catalog No.:BCC1163
CAS No.:372196-77-5
- Sieber Linker
Catalog No.:BCC2835
CAS No.:3722-51-8
- Wilforgine
Catalog No.:BCN5427
CAS No.:37239-47-7
- Wilfortrine
Catalog No.:BCN3085
CAS No.:37239-48-8
- Wilfordine
Catalog No.:BCN3083
CAS No.:37239-51-3
- TCS OX2 29
Catalog No.:BCC7670
CAS No.:372523-75-6
- Sennoside C
Catalog No.:BCN1004
CAS No.:37271-16-2
YM201636, an inhibitor of retroviral budding and PIKfyve-catalyzed PtdIns(3,5)P2 synthesis, halts glucose entry by insulin in adipocytes.[Pubmed:19289105]
Biochem Biophys Res Commun. 2009 May 8;382(3):566-70.
Silencing of PIKfyve, the sole enzyme for PtdIns(3,5)P(2) biosynthesis that controls proper endosome dynamics, inhibits retroviral replication. A novel PIKfyve-specific inhibitor YM201636 disrupts retroviral budding at 800 nM, suggesting its potential use as an antiretroviral therapeutic. Because PIKfyve is also required for optimal insulin activation of GLUT4 surface translocation and glucose influx, we tested the outcome of YM201636 application on insulin responsiveness in 3T3L1 adipocytes. YM201636 almost completely inhibited basal and insulin-activated 2-deoxyglucose uptake at doses as low as 160 nM, with IC(50)=54+/-4 nM for the net insulin response. Insulin-induced GLUT4 translocation was partially inhibited at substantially higher doses, comparable to those required for inhibition of insulin-induced phosphorylation of Akt/PKB. In addition to PIKfyve, YM201636 also completely inhibited insulin-dependent activation of class IA PI 3-kinase. We suggest that apart from PIKfyve, there are at least two additional targets for YM201636 in the context of insulin signaling to GLUT4 and glucose uptake: the insulin-activated class IA PI 3-kinase and a here-unidentified high-affinity target responsible for the greater inhibition of glucose entry vs. GLUT4 translocation. The profound inhibition of the net insulin effect on glucose influx at YM201636 doses markedly lower than those required for efficient retroviral budding disruption warns of severe perturbations in glucose homeostasis associated with potential YM201636 use in antiretroviral therapy.
The PIKfyve inhibitor YM201636 blocks the continuous recycling of the tight junction proteins claudin-1 and claudin-2 in MDCK cells.[Pubmed:22396724]
PLoS One. 2012;7(3):e28659.
Tight junctions mediate the intercellular diffusion barrier found in epithelial tissues but they are not static complexes; instead there is rapid movement of individual proteins within the junctions. In addition some tight junction proteins are continuously being endocytosed and recycled back to the plasma membrane. Understanding the dynamic behaviour of tight junctions is important as they are altered in a range of pathological conditions including cancer and inflammatory bowel disease. In this study we investigate the effect of treating epithelial cells with a small molecule inhibitor (YM201636) of the lipid kinase PIKfyve, a protein which is involved in endocytic trafficking. We show that MDCK cells treated with YM201636 accumulate the tight junction protein claudin-1 intracellularly. In contrast YM201636 did not alter the localization of other junction proteins including ZO-1, occludin and E-cadherin. A biochemical trafficking assay was used to show that YM201636 inhibited the endocytic recycling of claudin-1, providing an explanation for the intracellular accumulation. Claudin-2 was also found to constantly recycle in confluent MDCK cells and treatment with YM201636 blocked this recycling and caused accumulation of intracellular claudin-2. However, claudin-4 showed negligible endocytosis and no detectable intracellular accumulation occurred following treatment with YM201636, suggesting that not all claudins show the same rate of endocytic trafficking. Finally, we show that, consistent with the defects in claudin trafficking, incubation with YM201636 delayed formation of the epithelial permeability barrier. Therefore, YM201636 treatment blocks the continuous recycling of claudin-1/claudin-2 and delays epithelial barrier formation.
Functional dissociation between PIKfyve-synthesized PtdIns5P and PtdIns(3,5)P2 by means of the PIKfyve inhibitor YM201636.[Pubmed:22621786]
Am J Physiol Cell Physiol. 2012 Aug 15;303(4):C436-46.
PIKfyve is an essential mammalian lipid kinase with pleiotropic cellular functions whose genetic knockout in mice leads to preimplantation lethality. Despite several reports for PIKfyve-catalyzed synthesis of phosphatidylinositol 5-phosphate (PtdIns5P) along with phosphatidylinositol-3,5-biphosphate [PtdIns(3,5)P(2)] in vitro and in vivo, the role of the PIKfyve pathway in intracellular PtdIns5P production remains underappreciated and the function of the PIKfyve-synthesized PtdIns5P pool poorly characterized. Hence, the recently discovered potent PIKfyve-selective inhibitor, the YM201636 compound, has been solely tested for inhibiting PtdIns(3,5)P(2) synthesis. Here, we have compared the in vitro and in vivo inhibitory potency of YM201636 toward PtdIns5P and PtdIns(3,5)P(2). Unexpectedly, we observed that at low doses (10-25 nM), YM201636 inhibited preferentially PtdIns5P rather than PtdIns(3,5)P(2) production in vitro, whereas at higher doses, the two products were similarly inhibited. In cellular contexts, YM201636 at 160 nM inhibited PtdIns5P synthesis twice more effectively compared with PtdIns(3,5)P(2) synthesis. In 3T3L1 adipocytes, human embryonic kidney 293 and Chinese hamster ovary (CHO-T) cells, levels of PtdIns5P dropped by 62-71% of the corresponding untreated controls, whereas those of PtdIns(3,5)P(2) fell by only 28-46%. The preferential inhibition of PtdIns5P versus PtdIns(3,5)P(2) at low doses of YM201636 was explored to probe contributions of the PIKfyve-catalyzed PtdIns5P pool to insulin-induced actin stress fiber disassembly in CHO-T cells, GLUT4 translocation in 3T3L1 adipocytes, and induction of aberrant cellular vacuolation in these or other cell types. The results provide the first experimental evidence that the principal pathway for PtdIns5P intracellular production is through PIKfyve and that insulin effect on actin stress fiber disassembly is mediated entirely by the PIKfyve-produced PtdIns5P pool.
